Insight
Nico Gagelmann, China vs USA
Nico Gagelmann/X

Nico Gagelmann: Closing the Gap – PTCy Boosts Survival After Mismatched Stem Cell Transplants

Nico Gagelmann, Young National Society Ambassador at European Hematology Association (EHA) and Chair of the CAR-T for plasma cell disorder committee at The EBMT, shared a post on X:

“Out now in Journal of Clinical Oncology.
Closing the Gap: PTCy Boosts Survival After Mismatched Stem Cell Transplants
Summary:
In a multicenter phase II trial, post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis enabled strong 1-year survival outcomes in patients receiving peripheral blood stem cell transplants from HLA-mismatched unrelated donors (MMUDs).
Among 145 patients – 59% from underrepresented groups – 1-year overall survival reached 83.8% (MAC) and 78.6% (RIC/NMA), with low rates of severe GVHD.
Outcomes were comparable regardless of the degree of mismatch. These findings suggest PTCy regimens can safely expand donor access across all ethnic backgrounds.”

Nico Gagelmann

More posts featuring Nico Gagelmann on OncoDaily.

Abeer Madbouly Alison Loren Antonio Martin Jimenez Jimenez ASCO Brent Logan Brian C. Shaffer Bronwen E. Shaw cancer Craig Malmberg Dipenkumar Modi EHA Erin Leckrone European Hematology Association Farhad Khimani Heather E. Stefanski Janelle Olson Jeffery J. Auletta Jianqun Kou Journal of Clinical Oncology Juan Wu Karen Ballen Karilyn Larkin Larisa Broglie Mahasweta Gooptu Martin Maiers Medhat Askar Mehdi Hamadani Monzr M. Al Malki Muna Qayed Nico Gagelmann OncoDaily Oncology post-transplant cyclophosphamide PTCy Rachel Cook Rachel Cusatis Sally Arai Sarah Smith Stem Cell Transplants Stephanie Bo-Subait Stephanie Fingerson Stephen R. Spellman Steven Michael Devine Sung Won Choi The EBMT